These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15167911)

  • 1. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
    Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
    Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
    Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
    Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological & molecular profile of acute myelogenous leukaemia in India.
    Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
    Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress.
    Libura M; Asnafi V; Tu A; Delabesse E; Tigaud I; Cymbalista F; Bennaceur-Griscelli A; Villarese P; Solbu G; Hagemeijer A; Beldjord K; Hermine O; Macintyre E
    Blood; 2003 Sep; 102(6):2198-204. PubMed ID: 12791658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
    Sheikhha MH; Awan A; Tobal K; Liu Yin JA
    Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
    Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
    Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
    Kainz B; Heintel D; Marculescu R; Schwarzinger I; Sperr W; Le T; Weltermann A; Fonatsch C; Haas OA; Mannhalter C; Lechner K; Jaeger U
    Hematol J; 2002; 3(6):283-9. PubMed ID: 12522450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH
    Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
    Boissel N; Cayuela JM; Preudhomme C; Thomas X; Grardel N; Fund X; Tigaud I; Raffoux E; Rousselot P; Sigaux F; Degos L; Castaigne S; Fenaux P; Dombret H
    Leukemia; 2002 Sep; 16(9):1699-704. PubMed ID: 12200684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
    Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
    Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 mutations in myeloid sarcoma.
    Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
    Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
    Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
    Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.